CA2918092C - Anticorps monoclonaux et utilisation de ceux-ci - Google Patents

Anticorps monoclonaux et utilisation de ceux-ci Download PDF

Info

Publication number
CA2918092C
CA2918092C CA2918092A CA2918092A CA2918092C CA 2918092 C CA2918092 C CA 2918092C CA 2918092 A CA2918092 A CA 2918092A CA 2918092 A CA2918092 A CA 2918092A CA 2918092 C CA2918092 C CA 2918092C
Authority
CA
Canada
Prior art keywords
seq
antibody
amino acid
chain variable
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2918092A
Other languages
English (en)
Other versions
CA2918092A1 (fr
Inventor
Boris Labkovsky
Stefan Barghorn
Heinz Hillen
Ulrich Ebert
Andreas Striebinger
Patrick Keller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Deutschland GmbH and Co KG
AbbVie Inc
Original Assignee
AbbVie Deutschland GmbH and Co KG
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Deutschland GmbH and Co KG, AbbVie Inc filed Critical AbbVie Deutschland GmbH and Co KG
Priority claimed from CA2631195A external-priority patent/CA2631195C/fr
Publication of CA2918092A1 publication Critical patent/CA2918092A1/fr
Application granted granted Critical
Publication of CA2918092C publication Critical patent/CA2918092C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

La présente invention concerne des anticorps monoclonaux (par exemple, 8F5 et 8C5) qui peuvent être utilisés, par exemple, pour empêcher, traiter et diagnostiquer la maladie dAlzheimer ou dautres maladies neurodégénératives.
CA2918092A 2005-11-30 2006-11-30 Anticorps monoclonaux et utilisation de ceux-ci Active CA2918092C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US74086605P 2005-11-30 2005-11-30
US60/740,866 2005-11-30
US77895006P 2006-03-03 2006-03-03
US60/778,950 2006-03-03
CA2631195A CA2631195C (fr) 2005-11-30 2006-11-30 Anticorps monoclonaux et utilisation de ceux-ci

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2631195A Division CA2631195C (fr) 2005-11-30 2006-11-30 Anticorps monoclonaux et utilisation de ceux-ci

Publications (2)

Publication Number Publication Date
CA2918092A1 CA2918092A1 (fr) 2007-06-07
CA2918092C true CA2918092C (fr) 2020-07-14

Family

ID=50779222

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2918092A Active CA2918092C (fr) 2005-11-30 2006-11-30 Anticorps monoclonaux et utilisation de ceux-ci

Country Status (7)

Country Link
CN (2) CN105924521A (fr)
CA (1) CA2918092C (fr)
DK (1) DK2289909T3 (fr)
ME (1) ME01826B (fr)
NZ (1) NZ629387A (fr)
SI (3) SI2289909T1 (fr)
UA (1) UA95933C2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020027055A2 (pt) * 2018-07-17 2021-04-06 Jiangsu Hengrui Medicine Co., Ltd. Anticorpo anti-abeta, fragmento de ligação ao antígeno do mesmo e aplicação dos mesmos
CN109374902A (zh) * 2018-10-08 2019-02-22 杭州康知生物科技有限公司 一种定量检测IgG4的乳胶增强免疫比浊试剂盒及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
WO1999060024A1 (fr) * 1998-05-21 1999-11-25 The University Of Tennessee Research Corporation Procede d'elimination d'amyloide a l'aide d'anticorps anti-amyloide
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung

Also Published As

Publication number Publication date
NZ629387A (en) 2016-01-29
CN105924521A (zh) 2016-09-07
ME01826B (me) 2014-12-20
SI2289909T1 (sl) 2015-03-31
SI1976877T1 (sl) 2014-05-30
CN106008712A (zh) 2016-10-12
CA2918092A1 (fr) 2007-06-07
DK2289909T3 (en) 2015-02-02
SI1954718T1 (sl) 2015-01-30
UA95933C2 (ru) 2011-09-26

Similar Documents

Publication Publication Date Title
US20220017607A1 (en) Monoclonal antibodies against amyloid beta protein and uses thereof
CA2918092C (fr) Anticorps monoclonaux et utilisation de ceux-ci
AU2014277712B2 (en) Monoclonal antibodies against amyloid beta protein and uses thereof
AU2022201264A1 (en) Monoclonal antibodies against amyloid beta protein and uses thereof
MX2008007006A (es) Anticuerpos monoclonales contra la proteina amiloide beta y usos de los mismos

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160118